PUBLISHER: DelveInsight | PRODUCT CODE: 1125988
PUBLISHER: DelveInsight | PRODUCT CODE: 1125988
"SPRAVATO Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SPRAVATO for Treatment Resistant Depression in seven major markets. A detailed picture of the SPRAVATO for Treatment Resistant Depression in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the SPRAVATO for Treatment Resistant Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SPRAVATO market forecast analysis for Treatment Resistant Depression in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Treatment Resistant Depression.
Spravato contains esketamine hydrochloride, a noncompetitive N-methyl D-aspartate (NMDA) receptor antagonist. Esketamine is the S-enantiomer of racemic ketamine. The chemical name is (S)-2-(o-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. Its molecular formula is C13H16ClNO.HCl and its molecular weight are 274.2. Esketamine hydrochloride is a white or almost white crystalline powder that is freely soluble in water and methanol and soluble in ethanol. Spravato nasal spray is intended for nasal administration. Esketamine hydrochloride is contained as a solution in a stoppered glass vial within the nasal spray device. Each device delivers two sprays with a total of 32.3 mg of esketamine hydrochloride (equivalent to 28 mg of esketamine) in 0.2 mL of a clear, colorless aqueous solution with a pH of 4.5
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SPRAVATO Analytical Perspective by DelveInsight
This report provides a detailed market assessment of SPRAVATO for Treatment Resistant Depression in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2019 to 2032.
The report provides the clinical trials information of SPRAVATO for Treatment Resistant Depression covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions